SCHEMBL30047795

SCHEMBL30047795

COc1ccccc1S(=O)(=O)N(C)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.53
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
ACHE P22303 2/20 0.44
CA12 O43570 1/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
NFE2L2 Q16236 4/20 0.42
KCNH2 Q12809 1/20 0.42
KDM4E B2RXH2 3/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
DUSP3 P51452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23409893 1.00 HTR6 (0.53) HTR6CA1CA2ACHECA12
SCHEMBL8602545 0.85 HTR6 (0.56) HTR6CA1CA2CA12CA4
Hydrochloric Acid SCHEMBL30989178 0.83 HTR6 (0.55) HTR6CA1CA2CA12CA4
SCHEMBL28695161 0.81 HTR6 (0.53) HTR6CA1CA2CA12CA4
SCHEMBL29268394 0.80 HTR6 (0.51) HTR6CA1CA2CA12CA4
SCHEMBL3819213 0.79 KMT2A (0.57) HTR6CA12CA9KDM4EPOLB
SCHEMBL8549992 0.77 HTR6 (0.53) HTR6CA1CA2CA12CA7
SCHEMBL13588814 0.77 HTR6 (0.56) HTR6CA1CA2ACHECA12
SCHEMBL15473886 0.76 HTR6 (0.47) HTR6KDM4EPOLBHTTALDH1A1
SCHEMBL31352974 0.76 HTR6 (0.77) HTR6CA1CA2CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022249006-A1 USE OF 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS NOVARTIS AG (CH) 2022-12-01 WO disclosed
EP-4065228-A1 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS Novartis AG (CH) 2022-10-05 EP disclosed